Gland Pharma reports decline in Q1 FY23 consolidated PAT to Rs. 229.16 crores

Gland Pharma Limited has reported Consolidated financial results for the period ended June 30, 2022.

Financial Results (Q1 FY2023) - QoQ Comparison

The company has reported total income of Rs. 931.289 crores during the period ended June 30, 2022 as compared to Rs. 1168.248 crores during the period ended March 31, 2022.

The company has posted net profit / (loss) of Rs. 229.169 crores for the period ended June 30, 2022 as against net profit / (loss) of Rs. 285.902 crores for the period ended March 31, 2022.

The company has reported EPS of Rs. 13.92 for the period ended June 30, 2022 as compared to Rs. 17.36 for the period ended March 31, 2022.

Financials	Q1 FY2023	Q4 FY2022	% Change
Total Income	₹ 931.289 crs	₹1168.248 crs	-20.28%
Net Profit	₹229.169 crs	₹285.902 crs	-19.84%
EPS	₹13.92	₹17.36	-19.82%

Financial Results (Q1 FY2023) - YoY Comparison

The company has reported total income of Rs. 931.289 crores during the period ended June 30, 2022 as compared to Rs.1215.738 crores during the period ended June 30, 2021.

The company has posted net profit / (loss) of Rs.229.169 crores for the period ended June 30, 2022 as against net profit / (loss) of Rs.350.652 crores for the period ended June 30, 2021.

The company has reported EPS of Rs.13.92 for the period ended June 30, 2022 as compared to Rs.21.37 for the period ended June 30, 2021.

Financials	Q1 FY2023	Q1 FY2022	% Change
Total Income	₹ 931.289 crs	₹1215.738 crs	-23.40%
Net Profit	₹229.169 crs	₹350.652 crs	-34.64%
EPS	₹13.92	₹21.37	-34.86%

Shares of Gland Pharma Limited was last trading in BSE at Rs. 2473.30 as compared to the previous close of Rs. 2446.45. The total number of shares traded during the day was 4977 in over 1345 trades.

The stock hit an intraday high of Rs. 2515.40 and intraday low of 2464.05. The net turnover during the day was Rs. 12354194.00.

Source : Equity Bulls

Keywords

GlandPharma Q1FY23 ResultUpdate